Harvard Bioscience (NASDAQ:HBIO) Shares Pass Below 200 Day Moving Average of $4.50

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.50 and traded as low as $4.15. Harvard Bioscience shares last traded at $4.44, with a volume of 192,772 shares changing hands.

Harvard Bioscience Stock Up 4.7 %

The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.42. The stock has a 50 day simple moving average of $4.38 and a 200 day simple moving average of $4.50. The stock has a market cap of $192.70 million, a price-to-earnings ratio of -55.49 and a beta of 1.42.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, March 7th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%. The firm had revenue of $28.15 million during the quarter, compared to analyst estimates of $27.80 million. As a group, analysts expect that Harvard Bioscience, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA lifted its holdings in shares of Harvard Bioscience by 47.6% in the second quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 3,200 shares in the last quarter. Prudential Financial Inc. bought a new position in shares of Harvard Bioscience in the second quarter valued at approximately $37,000. Public Employees Retirement System of Ohio bought a new position in shares of Harvard Bioscience in the third quarter valued at approximately $40,000. Barclays PLC bought a new stake in Harvard Bioscience during the second quarter worth $43,000. Finally, Lazard Asset Management LLC lifted its holdings in Harvard Bioscience by 230.5% during the first quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock worth $44,000 after acquiring an additional 4,966 shares during the period. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.